Shots: This approval is based on data from DURATION-NEO-1 enrolling 375 patients for duration of 28 wks and DURATION-NEO-2, showing its safety and efficacy The study involves evaluation of Bydureon BCise IV qw, showing (reduction in HbA1c with 1.4% vs. 1.0% for Byetta BID IV for 28 wks.); (reduction in mean wt. 1.5 Kg vs. […]Read More
